Otsuka Corporation published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 30, 2026 at 06:39 UTC. Otsuka Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice. Search for news Close July 27 JUL 2026 Nutraceuticals Otsuka Foods to Launch New “My Size Plus Support W (Double)” Delivering Nutritional Support and Salt Control in One Product Available at Dispensing Pharmacies and Select Drugstores across Japan on July 31, 2026 July 15, 2026 Otsuka Holdings In transcending expectations and going above and beyond—under any circumstances—for patients, families, providers, and for each other. 建設戦略サミット2026春 未来を先取りするAI×デジタルツール最前線 業務効率化やDX投資判断に必要な視点を短時間で把握できます 本イベントは、「未来を先取りするAI×デジタルツール最前線」をテーマに、建設業におけるDXの最新動向と実践事例などをご紹介するオンラインイベントです。 July 29, 2026 Otsuka Foods Otsuka Foods to Launch Micro Magic French Fries: Black Pepper A New Flavor for Adults, Microwavable in the Box, Perfect with Drinks In Stores across Japan from August 24, 2026 July 27, 2026 Otsuka Pharmaceutical 大塚化学について About Otsuka Chemical 大塚化学は、地球環境と豊かな暮らしに 貢献する企業であり続けるため、 一人一人がコンプライアンスを遵守し、 更に「ユニーク」な製品を生み出す 会社を目指してまいります。 Investor Relations (IR) Information for shareholders and potential investors such as financial information and stock information of OTSUKA CORPORATION. For the fiscal year ending December 2026, Otsuka Shokai forecasts revenue of ¥1.31 trillion, essentially flat year-over-year, with operating profit expected to remain stable at around ¥90 billion. The company plans to further increase its dividend to ¥95 per share for FY2026. Key Milestones: VERA's atacicept has a PDUFA date of July 7, 2026; Vertex's povetacicept is expected to be approved in December 2026. Recommended Asset Positions Otsuka Holdings (4578.T): Buy rating, target price 12,400 yen. Reason: Voyxact as a key growth driver, strong launch performance, aligning with blockbuster drug expectations.